Here's Why Shareholders Will Not Be Complaining About Ascentage Pharma Group International's (HKG:6855) CEO Pay Packet
May 12
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedMay 14, 2025
DataAggregated Company Financials
Companies52
- 7D-6.4%
- 3M42.4%
- 1Y38.8%
- YTD36.3%
Over the last 7 days, the Biotech industry has dropped 6.4%, driven by a pullback from Innovent Biologics of 7.9%. Meanwhile, CARsgen Therapeutics Holdings actually outperformed within the industry, gaining 14% in the last week. In the past year, the industry has gained 39%. As for the next few years, earnings are expected to grow by 44% per annum.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 14 May 2025 | HK$551.1b | HK$61.5b | -HK$11,827,803,492.49 | 28.8x | -46.6x | 9x |
| Fri, 11 Apr 2025 | HK$470.7b | HK$57.9b | -HK$10,782,009,538.44 | 24.3x | -43.7x | 8.1x |
| Sun, 09 Mar 2025 | HK$461.2b | HK$52.5b | -HK$16,893,132,103.38 | 22.7x | -27.3x | 8.8x |
| Tue, 04 Feb 2025 | HK$356.8b | HK$52.3b | -HK$17,405,043,276.95 | 12.2x | -20.5x | 6.8x |
| Thu, 02 Jan 2025 | HK$375.7b | HK$51.8b | -HK$17,222,165,898.88 | 10.8x | -21.8x | 7.2x |
| Sat, 30 Nov 2024 | HK$399.6b | HK$52.3b | -HK$17,398,567,743.25 | 10.7x | -23x | 7.6x |
| Mon, 28 Oct 2024 | HK$407.7b | HK$52.3b | -HK$17,906,139,733.71 | 11.8x | -22.8x | 7.8x |
| Wed, 25 Sep 2024 | HK$348.9b | HK$52.9b | -HK$18,401,448,123.60 | 10.9x | -19x | 6.6x |
| Fri, 23 Aug 2024 | HK$328.7b | HK$51.7b | -HK$18,600,746,589.69 | 11.8x | -17.7x | 6.4x |
| Sun, 21 Jul 2024 | HK$324.3b | HK$49.6b | -HK$19,438,335,694.28 | 12.6x | -16.7x | 6.5x |
| Tue, 18 Jun 2024 | HK$341.0b | HK$49.7b | -HK$19,476,075,499.44 | 10.6x | -17.5x | 6.9x |
| Thu, 16 May 2024 | HK$373.3b | HK$49.9b | -HK$19,418,359,295.07 | 12.3x | -19.2x | 7.5x |
| Sat, 13 Apr 2024 | HK$341.5b | HK$49.6b | -HK$19,926,257,322.48 | 11x | -17.1x | 6.9x |
| Mon, 11 Mar 2024 | HK$338.7b | HK$47.3b | -HK$20,418,447,291.16 | 16.1x | -16.6x | 7.2x |
| Wed, 07 Feb 2024 | HK$313.5b | HK$47.2b | -HK$20,416,983,102.59 | 15.7x | -15.4x | 6.6x |
| Fri, 05 Jan 2024 | HK$389.3b | HK$46.9b | -HK$20,260,981,613.00 | 17.3x | -19.2x | 8.3x |
| Sun, 03 Dec 2023 | HK$427.8b | HK$47.0b | -HK$20,310,389,111.00 | 18.9x | -21.1x | 9.1x |
| Tue, 31 Oct 2023 | HK$414.6b | HK$45.0b | -HK$18,749,009,344.00 | 13.8x | -22.1x | 9.2x |
| Thu, 28 Sep 2023 | HK$417.5b | HK$44.9b | -HK$19,089,046,920.00 | 14.5x | -21.9x | 9.3x |
| Sat, 26 Aug 2023 | HK$373.2b | HK$37.6b | -HK$21,023,596,933.00 | 15.7x | -17.7x | 9.9x |
| Mon, 24 Jul 2023 | HK$397.4b | HK$35.5b | -HK$23,335,379,677.00 | 25.7x | -17x | 11.2x |
| Wed, 21 Jun 2023 | HK$404.6b | HK$35.5b | -HK$23,383,805,200.00 | 25.2x | -17.3x | 11.4x |
| Fri, 19 May 2023 | HK$429.7b | HK$36.1b | -HK$23,867,468,061.00 | 32.1x | -18x | 11.9x |
| Sun, 16 Apr 2023 | HK$469.8b | HK$37.1b | -HK$24,226,204,473.00 | 18.7x | -19.4x | 12.7x |
| Tue, 14 Mar 2023 | HK$381.2b | HK$33.2b | -HK$36,429,407,998.00 | 22.5x | -10.5x | 11.5x |
| Thu, 09 Feb 2023 | HK$450.9b | HK$34.9b | -HK$35,331,840,160.00 | 28.4x | -12.8x | 12.9x |
| Sat, 07 Jan 2023 | HK$426.1b | HK$34.6b | -HK$34,885,027,954.00 | 30.8x | -12.2x | 12.3x |
| Mon, 05 Dec 2022 | HK$360.0b | HK$33.4b | -HK$33,663,153,817.00 | 22.3x | -10.7x | 10.8x |
| Wed, 02 Nov 2022 | HK$338.0b | HK$33.3b | -HK$31,997,393,655.00 | 17.3x | -10.6x | 10.1x |
| Fri, 30 Sep 2022 | HK$287.4b | HK$33.7b | -HK$32,173,292,026.00 | 18.1x | -8.9x | 8.5x |
| Sun, 28 Aug 2022 | HK$334.1b | HK$33.6b | -HK$37,916,598,169.00 | 10.4x | -8.8x | 9.9x |
| Tue, 26 Jul 2022 | HK$343.1b | HK$32.9b | -HK$46,305,413,242.00 | 13.4x | -7.4x | 10.4x |
| Thu, 23 Jun 2022 | HK$363.0b | HK$33.1b | -HK$46,724,776,560.00 | 14.2x | -7.8x | 11x |
| Sat, 21 May 2022 | HK$352.1b | HK$34.0b | -HK$45,860,529,185.00 | 14.1x | -7.7x | 10.3x |
Price to Earnings Ratio
-7.7x
Current Industry PE
- Investors are relatively neutral on the Hong Kong Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 9.1x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 22% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 2.09% | |
| Healthcare | -3.00% | |
| Biotech | -6.38% | |
| Biotech | -6.38% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2171 CARsgen Therapeutics Holdings | HK$19.08 | 13.6% +HK$1.3b | 209.7% | PS246.1x | |
| 2511 HighTide Therapeutics | HK$3.09 | 30.4% +HK$370.6m | -55.5% | PB3.5x | |
| 2179 Jiangsu Recbio Technology | HK$9.00 | 8.4% +HK$334.2m | -2.1% | PS147x | |
| 1167 Jacobio Pharmaceuticals Group | HK$4.25 | 9.8% +HK$299.7m | 133.5% | PS19.9x | |
| 2561 VISEN Pharmaceuticals | HK$46.20 | 4.5% +HK$227.9m | n/a | PS43.6x |
